KALVISTA PHARMACEUTICALS INC (KALV) Stock News

USA - NASDAQ:KALV - US4834971032 - Common Stock

14.86 USD

+1.24 (+9.1%)

Last: 11/17/2025, 8:00:02 PM

14.84 USD

-0.02 (-0.13%)

After Hours: 11/17/2025, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

KALV Latest News, Press Relases and Analysis

All

Press Releases

7 days ago - By: Zacks Investment Research - Mentions: MGX

KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Tops Revenue Estimates

7 days ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results

8 days ago - By: Benzinga

Examining the Future: KalVista Pharma's Earnings Outlook

12 days ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting

13 days ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

15 days ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025

19 days ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

a month ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe

2 months ago - By: Stocktwits - Mentions: VFMO VTWG

News Image

KalVista Pharmaceuticals’ Hereditary Angioedema Drug Approved In EU, Switzerland: Retail Sees Stock Rallying To $22 In A Year

a month ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer

2 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors

2 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress

2 months ago - By: Benzinga

KalVista Pharma's Earnings: A Preview

2 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031

2 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes

2 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema

2 months ago - By: The Motley Fool

KalVista Posts 154% Expense Jump in Q1

2 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results

2 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals to Provide Operational Update and Fiscal Quarter Financial Results on September 11, 2025

2 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2025

3 months ago - By: Metagenomi, Inc. - Mentions: MGX

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

3 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union

4 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks

4 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

4 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results